Document:

<PAGE>

                                                                   EXHIBIT 10.19

--------------------------------------------------------------------------------
STOCK OPTION AGREEMENT                      SYNAVANT  INC.

                                            Employer ID: ________
                                            3445 Peachtree Rd. NE, Suite 1400
                                            Atlanta, GA  30326
--------------------------------------------------------------------------------

                                            PLAN:          ST00
                                            -----------------------

THIS DOCUMENT CONSTITUTES PART OF A PROSPECTUS COVERING SECURITIES THAT HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933

--------------------------------------------------------------------------------

Synavant Inc. (the "Company") hereby grants to you a non-qualified stock option
to purchase ________ shares of the Company's common stock at $_________ per
share (your "Option"). This grant is effective as of _______________ (the "Date
of Grant").

Your Option is subject to and governed by the terms of the Company's 2000 Stock
Incentive Plan (the "Plan") document. The provisions of the Plan document are
incorporated into this Stock Option Agreement (the "Agreement") by reference.
All capitalized terms used in this Agreement but not defined shall have the
meanings set forth in the Plan document. In the event the Plan document and this
Agreement conflict with one another, the terms of the Plan document shall
govern.

VESTING AND STATED EXPIRATION DATE

Your Option will vest and become exercisable according to the following schedule
if your employment with the Company or a Subsidiary continues through the
vesting date; provided, however, that the terms of the Plan providing for
accelerated vesting upon specified terminations of employment shall apply to the
Option:

     Number                                          Stated
     Of Shares                Vest Date              Expiration Date
     ---------------------    ---------------        -------------------------

In the event your employment with or service to the Company and its Subsidiaries
terminates, any portion of the Option not vested at or before termination will
be forfeited, except as otherwise provided in the Plan. The Option (or
applicable portion thereof) shall expire at the stated expiration date, subject
to earlier forfeiture or expiration as specified in the Plan and this Agreement.

<PAGE>

EXERCISE OF OPTIONS

You may exercise your Option, at such time as it has become exercisable, only in
accordance with the Plan and with any procedures that the Committee may set
forth.

Notwithstanding anything to the contrary in this Award Agreement, upon
occurrence of a "Change in Control" (as such term is defined in the Plan), then
any unvested portion of the Option (not previously forfeited) will become
immediately vested and the Option will become immediately exercisable in full
and, if your employment with or service to the Company and its Subsidiaries
thereafter terminates for any reason other than by the Company (or Subsidiary)
for "Cause," the unexercised portion of your Option may thereafter be exercised
until the Option's stated expiration date (except as provided below if you
engage in Detrimental Activities). For purposes of this Agreement, "Cause" shall
have the meaning set forth in any Change-in-Control Agreement between you and
the Company in effect at the date of the Change in Control or, if no such
agreement is then in effect, "Cause" shall mean termination on account of (A)
the willful and continued failure by you to substantially perform your duties
with the Company (other than any such failure resulting from your incapacity due
to physical or mental illness or disability or any failure after the issuance of
a Notice of Termination by you for Good Reason) which failure is demonstrably
and materially damaging to the financial condition or reputation of the Company
and/or its subsidiaries, and which failure continues more than 48 hours after a
written demand for substantial performance is delivered to you by the Board,
which demand specifically identifies the manner in which the Board believes that
you have not substantially performed your duties or (B) the willful engaging by
you in conduct which is demonstrably and materially injurious to the Company,
monetarily or otherwise. No act, or failure to act, on your part shall be deemed
"willful" unless done, or omitted to be done, by you not in good faith and
without reasonable belief that your action or omission was in the best interest
of the Company. This provision supercedes the default termination provisions set
forth in Section 6 of the Plan.

Your sales of shares acquired upon exercise of the Option will be subject to
applicable restrictions under the Company's policies regulating insider trading
by employees.

NONTRANSFERABILITY OF OPTION

Except as otherwise may be provided under the Plan, you cannot transfer, give or
assign your Option to anyone except after your death by your will or by
applicable inheritance laws, and during your lifetime your Option shall be
exercisable only by you.

FORFEITURE OF UNEXERCISED PORTION OF OPTION.

If you directly or indirectly engage in any of the following activities
("Detrimental Activities"), without the written consent of the Company, while
you are working for the Company or any of its affiliates (each, a "Synavant
Company") or after you leave (to the extent provided below):

     -    using or disclosing any information that has been treated by an
          Synavant Company as confidential or proprietary and is of competitive
          advantage to such Synavant Company, unless you are using or
          disclosing it in the course of your job with such Synavant Company,

     -    during your employment or the twelve months after you leave your
          employment with any Synavant Company, soliciting for anyone other
          than an Synavant Company the trade or business of any entity that
          was a customer, prospective customer or supplier of a Synavant
          Company during the period that you worked for any Synavant Company,

                                       2
<PAGE>

     -    during your employment or the twelve months after you leave your
          employment with any Synavant Company, soliciting any employee of any
          Synavant Company to leave his or her employment; or employing or
          otherwise using the services of any person who is or was a Synavant
          Company employee during the last twelve months that you worked for a
          Synavant Company, or

     -    during your employment or the twelve months after you leave your
          employment with any Synavant Company, directly or indirectly
          (including without limitation as an officer, director, employee,
          advisor, consultant or investor), (i) seeking or accepting any
          employment or other work with or providing assistance to any person
          or entity that offers Competitive Services (as defined below) to any
          person or entity that was a customer or potential customer of any
          Synavant Company at any time during the last two years of your
          employment with any Synavant Company, or (ii) otherwise providing
          Competitive Services;

the unexercised portion of your Option shall automatically expire (regardless of
vesting) on the date on which you enter into the Detrimental Activity.

                                       3
<PAGE>

For purposes hereof, "Competitive Services" means engaging in business
activities, anywhere in the world, which provide automated sales and marketing
support and interactive marketing services to the pharmaceutical and healthcare
industry, including using or developing technology similar to that which any ST
Company uses to process pharmaceutical or health care information, sales-force
management applications, decision-support tools, data-warehousing applications
and data-mining applications.

As a condition to the exercise of the Option, the Company may require Employee
to make any representation or warranty to the Company as may be required under
any applicable law or regulation, and to make a representation and warranty that
no Detrimental Activity has occurred or is contemplated within the meaning of
this Agreement.

ACKNOWLEDGMENT, AGREEMENT AND CONSENT

You acknowledge, agree and consent that the following are true:

(a)  The Plan is discretionary and the Company may amend, cancel or terminate
     the Plan at any time. The grant of your Option is a one-time benefit
     offered to you and does not create any contractual or other right for you
     to receive any grant of options or benefits under the Plan in the future.
     Future grants, if any, will be at the sole discretion of the Company,
     including, but not limited to, the timing of any grant, the number of
     options, vesting provisions and the exercise price; and

(b)  Your participation in the Plan is voluntary. The value of your Option is an
     extraordinary item of compensation outside the scope of your employment
     contract, if any. As such, your Option is NOT part of normal or expected
     compensation for purposes of calculating any severance, resignation,
     redundancy, end- of-service payments, bonuses, long-service awards, pension
     or retirement benefits or similar payments.

PERSONAL DATA AUTHORIZATION

You expressly authorize your employer to furnish the Company (and any agent of
the Company administering the Plan or providing Plan recordkeeping services)
with such information and data as it shall request in order to facilitate the
grant and exercise of your Option and to facilitate administration of the Plan.
In addition, you agree and consent that certain personal data concerning you and
your participation in the Plan will be transmitted and communicated outside the
country of your employment or residence in order that the Company may administer
the Plan.

GOVERNING LAW

The Plan and this Agreement shall be governed by the laws of the State of
Georgia without regard to its conflicts of law doctrine.

Any legal proceeding arising out of this Agreement shall be brought exclusively
in the federal or state courts located in the State of Georgia. You agree to
submit to personal jurisdiction and to venue in those courts. You further agree
to waive all legal challenges and defenses to the appropriateness of Georgia as
the site of any such legal proceeding and to the application of Georgia law.

ACCEPTANCE

                                       4
<PAGE>

You do not need to do anything if you want to accept your Options on the terms
set out in this Agreement. It would however help us if you would sign the
enclosed copy of this Agreement in the space indicated below and return a copy
to us by mail to:

         ------------------------

         ------------------------

         ------------------------

         ------------------------

         ------------------------

         ------------------------

If you do not want to accept your Option on the terms set out in this Agreement,
please write to the Company at the above address, marking your envelope to the
attention of _________________, no later than _______________. Your Option will
then be cancelled. If you do not write to us telling us that you do not want
your Option by _________________, we will assume that you want to accept your
Options and agree to the terms set out in this Agreement.

By signing below, you accept your Option as described above and the terms and
conditions set out in this Agreement, the Plan and all related documents. Copies
of the Plan and such related documents are being provided to you as part of this
Agreement.

SYNAVANT INC.

By:_____________________________                  __________________________
   Kevin Tarrant                                  Employee's Signature
   Chief Human Resources Officer

                                                  __________________________
                                                  PRINT NAME

                                       5<PAGE>

December 22, 1998

UNIVERSITY OF CALIFORNIA, BERKELEY

OFFICE OF TECHNOLOGY LICENSING                                          [SEAL]

-------------------------------------------------------------------------------
-------------------------------------------------------------------------------

                      AMENDED AND RESTATED EXCLUSIVE. LICENSE

                                       BETWEEN

                              ACACIA BIOSCIENCES, INC.

                                        AND

                     THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                         FOR

                                GENE REPORTER MATRIX

                                                       UC Case No.: B95-034

-------------------------------------------------------------------------------
-------------------------------------------------------------------------------

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

                                  TABLE OF CONTENTS
<TABLE>
<CAPTION>
SECTION   TITLE                                                                       PAGE
<S>       <C>                                                                         <C>
1.        BACKGROUND. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1

2.        DEFINITIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2

3.        GRANT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4

4.        SUBLICENSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4

5.        LICENSE ISSUE FEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6

6.        ROYALTIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6

7.        DUE DILIGENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7

8.        PROGRESS AND ROYALTY REPORTS. . . . . . . . . . . . . . . . . . . . . . . . . .9

9.        BOOKS AND RECORDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

10.       LIFE OF THE AGREEMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

11.       TERMINATION BY REGENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

12.       TERMINATION BY LICENSEE . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

13.       DISPOSITION OF PRODUCTS ON HAND UPON TERMINATION. . . . . . . . . . . . . . . 11

14.       PATENT PROSECUTION AND MAINTENANCE. . . . . . . . . . . . . . . . . . . . . . 11

15.       MARKING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

16.       USE OF NAMES AND TRADEMARKS . . . . . . . . . . . . . . . . . . . . . . . . . 13

17.       LIMITED WARRANTIES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

18.       PATENT INFRINGEMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

19.       INDEMNIFICATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

20.       EXPORT CONTROLS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

21.       FOREIGN GOVERNMENTAL APPROVAL OR REGISTRATION . . . . . . . . . . . . . . . . 15

22.       ASSIGNMENT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

23.       NOTICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

24.       LATE PAYMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

25.       WAIVER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

26.       CONFIDENTIALITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

27.       FORCE MAJEURE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

28.       SEVERABILITY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

29.       APPLICABLE LAW. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

30.       SCOPE OF AGREEMENT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
</TABLE>

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

UNIVERSITY OF CALIFORNIA, BERKELEY
OFFICE OF TECHNOLOGY LICENSING                                [SEAL]

-------------------------------------------------------------------------------
-------------------------------------------------------------------------------

                                 AMENDED AND RESTATED

                                 EXCLUSIVE LICENSE

                                      BETWEEN

                              ACACIA BIOSCIENCES, INC.

                                        AND

                    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                        FOR

                                 GENE REPORTER MATRIX

                                             UC Case No.: B95-034
                                             U.S. Patents 5,777,888
                                             and 5,569,588

-------------------------------------------------------------------------------
-------------------------------------------------------------------------------

Effective as of September 1, 1995 (the "EFFECTIVE DATE") and amended and
restated as of December 1, 1998 (the "RESTATEMENT DATE"), THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111
Franklin Street, Fifth Floor, Oakland, California 946xx, acting through its
Office of Technology Licensing, at the University of California, Berkeley, 2150
Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620 ("REGENTS") and ACACIA
BIOSCIENCES, INC., a Delaware corporation having a principal place of business
at 4136 Lakeside Drive, Richmond, California 94806 ("LICENSEE"), agree as
follows:

1.     BACKGROUND

       1.1    REGENTS has an assignment of the Genome Reporter Matrix for Drug
Discovery and Development invented by Jasper D. Rine, Ph.D., a molecular
geneticist employed by the University of California, Berkeley, and Matthew N.
Ashby, Ph.D., a postdoctoral fellow in Dr. Rifle's laboratory ("INVENTION"), as
described in REGENTS' Case No. B95-034 and REGENTS' PATENT RIGHTS as defined
below, which are directed to the INVENTION.

       1.2    LICENSEE entered into a Letter Agreement and extension thereof
with REGENTS effective January 13, 1995, terminating on October 13, 1995, for
the purpose of evaluating the INVENTION and granting LICENSEE an exclusive right
to negotiate an option or exclusive license of the INVENTION, which Letter
Agreement covers the LICENSEE's commitment to reimburse

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 1                       Confidential

<PAGE>

REGENTS' patent costs during the period of good-faith negotiation for an
exclusive license.

       1.3    LICENSEE provided REGENTS with an Executive Summary of its drug
discovery process and business strategy in order to evaluate its capabilities as
a LICENSEE to commercialize the INVENTION.

       1.4    The INVENTION was developed without Government support.

       1.5    Both parties recognize and agree that royalties due hereunder will
be paid to REGENTS on both pending patent applications and issued patents.

       1.6    REGENTS wish to have said INVENTION perfected and marketed at the
earliest possible time in order that products resulting therefrom may be
available for public use and benefit.

       1.7    LICENSEE wishes to acquire a license under the REGENTS' PATENT
RIGHTS for the purpose of undertaking development and to manufacture, use, and
distribute under license PRODUCTS as defined below.

       1.8    REGENTS have disclosed to LICENSEE certain information and
technical data pertaining to the INVENTION and such disclosure gives the
LICENSEE an economic advantage in bringing the INVENTION to market.

       1.9    LICENSEE and REGENTS entered into an Exclusive License Agreement
for Gene Reporter Matrix for New Drug Discovery, effective September 1, 1995
with respect to the INVENTION and the REGENTS' PATENT RIGHTS (the "ORIGINAL
AGREEMENT").  -

       1.10   LICENSEE and REGENTS desire to amend and restate certain
provisions of the ORIGINAL AGREEMENT as set forth in this Amended and Restated
Exclusive License Agreement for Gene Reporter Matrix in light of, inter alia,
changes in market conditions and changes in the sublicensing strategy of the
LICENSEE.

2.     DEFINITIONS

       2.1    "AGREEMENT" means this Amended and Restated Exclusive License
Agreement for Gene Reporter Matrix.

       2.2    "REGENTS' PATENT RIGHTS" means U.S. Patents 5,777,888 and
5,569,588 entitled, respectively, "Systems for Generating and Analyzing
Stimulus-Response Output Signal Matrices" and "Methods for Drug Screening"
filed by Drs. Rine and Ashby and assigned to REGENTS; and continuing
applications of the patent applications from which such Letters Patent
issued, including divisions, substitutions, extensions and
continuation-in-part applications (only to the extent, however, that claims
in the continuation-in-part applications are entitled to the priority filing
date of the parent patent application), any patents issuing on said
application or continuing applications including reissues; and any
corresponding foreign patents or applications.

       2.3    "LICENSED PRODUCTS AND SERVICES" means any product, service,
apparatus, kit or component part thereof or other material (i) produced by, or
used in, the LICENSED METHOD or (ii) the manufacture, use, sale, offer for sale
or importation of which in a particular country:

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 2                       Confidential
<PAGE>

              (a)    Is covered by a valid claim of an issued, unexpired patent
under the REGENTS' PATENT RIGHTS in that country in which such patent has issued
(claim of an issued, unexpired REGENTS' PATENT RIGHTS shall be presumed to be
valid unless and until it has been held to be invalid by a final judgment of a
court of competent jurisdiction from which no appeal can be or is taken) or;

              (b)    Is covered by a pending claim being prosecuted in a pending
patent application under the REGENTS' PATENT RIGHTS in that country in which
such application is pending.

       2.4    "LICENSED METHOD" means any process or method (i) that is covered
by the REGENTS' PATENT RIGHTS in the country in which such process or method is
used or (ii) the use or practice of which would constitute, but for the license
granted to the LICENSEE pursuant to this Agreement, an infringement of any
issued or pending claim within REGENTS' PATENT RIGHTS in that country in which
the LICENSED METHOD is used or practiced.

       2.5    "LICENSED FIELD OF USE" means use of the LICENSED PRODUCTS AND
SERVICES for any purpose, including without limitation, the identification,
discovery, development, optimization or characterization of genetic materials or
chemical compounds for diagnostic or therapeutic use, or for agricultural uses
such as pesticides, herbicides, and transgenic plant development.

       2.6    "NET LICENSEE REVENUES" means the gross revenues actually received
by LICENSEE from the sale, lease or distribution of LICENSED PRODUCTS AND
SERVICES by LICENSEE in the form in which they are sold, leased, used or
distributed under license, whether or not assembled (and without excluding
therefrom any components or subassemblies thereof, whatever their origin and
whether or not patent impacted), less the following items but only insofar as
they actually pertain to the disposition of such LICENSED PRODUCTS AND SERVICES
by LICENSEE and are included in such gross revenues, and (except Item d) are
separately billed:

              (a)    Import, export, excise, and sales taxes, plus custom
duties; if custom duties are part of the licensed price, REGENTS will accept
LICENSEE's statement to that effect provided accounting statement is supplied,
identifying each item and duty amount included.

              (b)    Costs of insurance, packing, and transportation from the
place of manufacture to the customer's premises or point of installation;

              (c)    Costs of installation at the place of use; and

              (d)    Credit for returns, allowances, or trades.

       2.7    "SUBLICENSING REVENUES" means the gross revenues actually received
by LICENSEE (whether in the form of upfront payments, license fees, license
maintenance fees, milestone payments, royalties, minimum royalties or advance
royalties) from its sublicensees of the REGENTS PATENT RIGHTS under this
Agreement to the extent received in consideration for the sublicensing of such
REGENTS PATENT RIGHTS. [***]

       (i) as research and development funding or support payments, to the
extent such payments are

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 3                       Confidential

<PAGE>

allocated for a specific research and development project or to the extent
such payments do not exceed LICENSEE's research and development costs for a
project, determined using the then-applicable full-time equivalent funding
rate for LICENSEE's research and development personnel (i.e., the rate
applicable to LICENSEE's personnel allocated to research and development
activities, including salary, benefits, materials, equipment, and allocated
overhead),

       (ii) for the purchase of an equity interest in LICENSEE at the fair
market value of such interest (with any premium paid by a sublicensee in excess
of such fair market value being included in SUBLICENSING REVENUES),

       (iii) as a loan to LICENSEE, to the extent that such loan is not
forgivable, and

       (iv) in the form of any advanced royalty payments or option payments to
LICENSEE that are refundable to such sublicensee. SUBLICENSING REVENUES
specifically excludes any NET LICENSEE REVENUES of LICENSEE.

       2.8    "LICENSED TERRITORY" means United States of America, its
territories and possessions, any foreign countries where REGENTS have filed or
obtained corresponding foreign patents or applications, and any other foreign
countries throughout the world for which REGENTS may lawfully grant a license of
REGENTS' PATENT RIGHTS.

3.     GRANT

       3.1    Subject to the limitations set forth in this Agreement REGENTS
hereby grants and LICENSEE hereby accepts an exclusive license under the
REGENTS' PATENT RIGHTS to make, have made, use, sell, offer for sale, import and
distribute under license LICENSED PRODUCTS AND SERVICES and to practice or use
the LICENSED METHOD in the LICENSED TERRITORY and in the LICENSED FIELD OF USE.

       3.2    The license under Article 3.1 shall be exclusive for a term
commencing as of the effective date of this Agreement and ending on the date of
the last to expire patent under the REGENTS' PATENT RIGHTS.

       3.3    REGENTS expressly reserves the non-transferrable right to use the
INVENTION and related technology solely for educational and noncommercial
research purposes provided, however, that REGENTS may extend such right to any
other non-profit entity.

       3.4    LICENSEE shall have a continuing responsibility to keep the
REGENTS informed of its large/small entity status (as defined by the United
States Patent and Trademark Office) of itself and its sublicensees.

4.     SUBLICENSES

       4.1    LICENSEE shall have the right to sublicense to third parties the
rights granted in Section 3.1 above, provided that LICENSEE has current
exclusive rights under this Agreement at the time of grant of such sublicense.
REGENTS and LICENSEE agree and understand that LICENSEE may sublicense the
REGENTS' PATENT RIGHTS in the following ways:

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 4                       Confidential

<PAGE>

       (i) by means of non-exclusive patent licenses to third party potential
infringers pursuant to an agreement under which LICENSEE is not obligated to
perform services or develop products as part of a collaborative project (a
"PATENT SUBLICENSE") and,

       (ii) by means of exclusive or non-exclusive arrangements with third party
collaborators for the discovery and development of lead compounds, target genes
or products wherein LICENSEE also provides to such third party technology or
services proprietary to LICENSEE (a "COLLABORATION AGREEMENT").

       If LICENSEE receives consideration for the grant of a sublicense pursuant
to a PATENT SUBLICENSE in a form other than cash, LICENSEE will pay royalties
pursuant to Section 6.1(ii) on such consideration on the fair market value of
such non-cash consideration. The parties intend that all SUBLICENSING REVENUES
that LICENSEE receives from third parties pursuant to a PATENT SUBLICENSE or a
COLLABORATION AGREEMENT shall be subject to the royalty provided in Section
6.1(ii), and not included in the calculation of NET LICENSEE REVENUES. For
clarification of LICENSEE's obligations under Section 6.1, if LICENSEE enters
into an agreement with a third party collaborator for the discovery and
development of lead compounds, target genes or products wherein LICENSEE
provides to such third party both:

       (A) technology or services that are not covered by the REGENTS' PATENT
RIGHTS and,

       (B) LICENSED PRODUCTS AND SERVICES, but such agreement does not
provide for such third party to obtain a sublicense under the REGENTS PATENT
RIGHTS, then such agreement shall not be a COLLABORATION AGREEMENT and shall
be subject to the obligations under Section 6.1(i).

       4.2    Every such sublicense shall contain at least the following:

              (a)    A statement setting forth the date upon which LICENSEE's
exclusive rights, privileges, and license hereunder shall expire.

              (b)    A statement such that the obligations of Articles 9.1, 10,
and 16 of this Agreement shall be binding upon the sublicensee as if it were in
place of LICENSEE,

              (c)    The same provision for indemnification of REGENTS as has
been provided for in this Agreement.

       4.3    Every PATENT SUBLICENSE shall contain the following:

                     (i)    A statement that such sublicensee(s) shall be
precluded from granting further sublicenses.

       4.4    Every COLLABORATION AGREEMENT shall contain the following:

                     (i)    A statement that such sublicensee(s) shall be
precluded from granting further sublicenses, except to its affiliates and except
as agreed upon by LICENSEE, and provided that such sublicensee promptly notifies
LICENSEE of any such sublicense, and that such sublicense is subject

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 5                       Confidential

<PAGE>

to the same terms as set forth in this Article 4.

       4.5    LICENSEE shall notify REGENTS of each sublicense granted hereunder
and furnish to REGENTS a summary of the non-confidential material terms of each
such sublicense agreement.

       4.6    LICENSEE shall deliver all reports due REGENTS and received from
sublicensees.

       4.7    Upon termination of this Agreement for any reason, all sublicenses
that are granted by LICENSEE pursuant to this Agreement shall remain in effect
and shall be assigned by LICENSEE to REGENTS except that REGENTS shall not be
bound to perform any duties or obligations set forth in any sublicenses that
extend beyond the duties and obligations of REGENTS set forth in this Agreement.

5.     LICENSE ISSUE FEE

       5.1    LICENSEE shall pay to REGENTS a non-creditable, non-refundable
license issue fee of $80,000 and 25,000 shares of common stock in accordance
with the following schedule:

              5.1.a  25,000 shares of common stock due within thirty (30) days
                     of the effective date of this Agreement;

              5.2.b  [***] of the effective date of this agreement;

              5.1.c  [***] of the effective date of this Agreement;

              5.1.d  [***] of the effective date of this Agreement;

              5.1.e  [***] upon obtaining cumulative equity financing of
                     [***];

              5.1.f  [***] at the time the first patent included within
                     REGENTS' PATENT RIGHTS is allowed; and

              5.1.g  [***] upon the first occurrence of NET LICENSEE REVENUES.

              The University acknowledges that prior to the Restatement Date,
LICENSEE has paid the portions of the license issue fee provided for in Sections
5.1(a) through 5.1(f). This fee is non-refundable and not an advance against
royalties.

6.     ROYALTIES

       6.1    LICENSEE shall pay to REGENTS earned royalties at the rate of
(i) [***] of all NET LICENSEE REVENUES and (ii) [***] of all SUBLICENSING
REVENUES.

       6.2    Royalties shall be payable on NET LICENSEE REVENUES and
SUBLICENSING REVENUES covered by both pending patent applications and issued
patents.

       6.3    Royalties accruing to the REGENTS shall be paid to the REGENTS
quarterly on or before the following dates of each calendar-year:

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 6                       Confidential

<PAGE>

                     February 28 for the calendar quarter ending December 31

                     May 31 for the calendar quarter ending March 31

                     August 31 for the calendar quarter ending June 30

                     November 30 for the calendar quarter ending September 30

       6.4    Beginning in the first calendar year after the first occurrence
of NET LICENSEE REVENUES and in each succeeding calendar year thereafter,
LICENSEE shall pay to the REGENTS a minimum annual royalty of [***] for the
life of this Agreement. This minimum annual royalty shall be paid to the
REGENTS by February 28 of each year and shall be credited against the earned
royalty due and owing on NET LICENSEE REVENUES under Section 6.1 for the
calendar year in which the minimum payment was made.

       6.5    All royalties due the REGENTS shall be payable in United States
funds collectible at par in San Francisco, California. When LICENSED PRODUCTS
AND SERVICES are sold for monies other than United States dollars, the earned
royalties will first be determined in the foreign currency of the country in
which the LICENSED PRODUCTS AND SERVICES were licensed and then converted into
equivalent United States funds. The exchange rate will be that rate quoted in
the Wall Street Journal on the last business day of the reporting period.

       6.6    Earned royalties on licensed distribution of LICENSED PRODUCTS AND
SERVICES occurring in any country outside the United States shall not be reduced
by any taxes, fees, or other charges imposed by the government of such country
on the remittance of royalty income. The LICENSEE shall also be responsible for
all bank transfer charges.

       6.7    LICENSEE shall make all payments under this Agreement by check
payable to "The Regents of the University of California" and forward it to
REGENTS at the address shown in Article 23.

       6.8    In the event that any patent or any claim thereof included within
the REGENTS' PATENT RIGHTS expires or shall be held invalid in a final decision
by a court of competent jurisdiction and last resort and from which no appeal
has been or can be taken, all obligation to pay royalties for LICENSED PRODUCTS
AND SERVICES based on, covered by, or made using such patent or claims or any
claims patentably indistinct therefrom shall cease as of the date of such
expiration or final decision. LICENSEE shall not, however, be relieved from
paying any royalties for LICENSED PRODUCTS AND SERVICES that accrued before such
expiration or decision or that are based on another valid patent or claim not
expired or involved in such decision.

7.     DUE DILIGENCE

       7.1    LICENSEE, upon execution of this Agreement, shall use diligent
commercial efforts to proceed with the development, manufacture, and
distribution under license of LICENSED PRODUCTS AND SERVICES and shall use
diligent commercial efforts to market them in quantities sufficient to meet the
market demand. LICENSEE shall be entitled to exercise prudent and reasonable
business judgment in meeting its due diligence obligations hereunder.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 7                       Confidential

<PAGE>

       7.2    LICENSEE specifically commits to achieving the following
objectives in its due diligence activities hereunder:

              (a)    Provide a business plan to REGENTS within [***] from the
effective date of this Agreement which demonstrates how LICENSEE plans to
acquire and apply the resources needed to commercialize the INVENTION;

              (b)    Establish a sponsored research program with the
University of California, Berkeley, within [***] of the effective date of
this Agreement to complete development and test the INVENTION. Should
permission to conduct a sponsored research program be denied by the campus
committee on conflict of interest, then THE REGENTS shall inform LICENSEE in
writing of this decision. LICENSEE must then provide a written plan to THE
REGENTS for the alternative development of the technology by another means
within sixty (60) days of the receipt of the notification from THE REGENTS.
THE REGENTS shall respond promptly to the alternative plan but if not
acceptable, then LICENSEE agrees to implement THE REGENTS' reasonable
requests.

              (c)    Develop and implement a patent strategy that results in
appropriate filings of additional patent applications covering inventions
relating to the INVENTION within [***] of the effective date of this
Agreement and meet any statutory bar deadlines due to publications by filing
appropriate patent applications;

              (d)    Establish a facility for the research, development,
sale, and marketing of LICENSED PRODUCTS AND SERVICES and LICENSED METHODS
within [***] of the effective date of this Agreement;

              (e)    Achieve either private, venture capital or corporate
research or equity financing in the minimum amount of [***] within thirty
(30) months of the effective date of this Agreement; and

              (f)    Have first occurrence of NET LICENSEE REVENUES within
[***] of the effective date of this Agreement.

              The University acknowledges that prior to the Restatement Date,
LICENSEE has achieved the requirements in this Article 7.2 (a) -(e).

       7.3    If LICENSEE is unable to meet any of its due diligence
obligations set forth in Article 7.2, then REGENTS shall so notify LICENSEE
of failure to perform. LICENSEE shall have the right and option to extend the
target date of any such due diligence obligation for a period of [***] upon
the payment of [***]of the extension date for each [***] extension option
exercised by LICENSEE. These payments are in addition to the minimum royalty
payments specified in Article 6.4. Should LICENSEE opt not to extend the
obligation or fail to meet it by the extended target date, then REGENTS shall
have the right and option either to terminate this Agreement or to reduce the
LICENSEE's exclusive license to a non-exclusive royalty bearing license. This
right, if exercised by REGENTS, supersedes the rights granted in Article 3.
The right to terminate this Agreement or reduce LICENSEE's exclusive license
granted hereunder to a non-exclusive license shall be REGENTS' sole remedy
for breach of Article 7. However, if LICENSEE is unable to perform any of the
due diligence obligations set forth in Article 7.2 due to hardships beyond
LICENSEE's control while LICENSEE has demonstrated diligent commercial
efforts to perform these obligations, then

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 8                       Confidential

<PAGE>

REGENTS may extend the dates as appropriate (after conferring with LICENSEE
in good faith and, in any event, on at least a day to day basis) in writing
to LICENSEE, and REGENTS shall not terminate this Agreement or reduce
LICENSEE's exclusive license to a non-exclusive license.

       7.4    At the request of either party, any controversy or claim arising
out of or relating to the diligence provisions of Article 7.2 shall be settled
by arbitration conducted in San Francisco, CA in accordance with the then
current Licensing Agreement Arbitration Rules of the American Arbitration
Association. Judgment upon the award rendered by the arbitrator(s) shall be
binding on the parties and may be entered by either party in the court or forum,
state or federal, having jurisdiction. In determination of due diligence, the
arbitrator may determine solely the issues of fact or law with respect to
termination of LICENSEE's or REGENTS' respective rights under this Agreement but
shall not have the authority to award monetary damages or grant equitable
relief.

       7.5    To exercise either the right to terminate this Agreement or to
reduce the license to a non-exclusive license for lack of diligence required
in Article 7.2, REGENTS must give LICENSEE written notice of the deficiency.
The LICENSEE thereafter has sixty (60) days to cure the deficiency or to
request arbitration. If REGENTS has not received a written request for
arbitration or satisfactory tangible evidence that the deficiency has been
cured by the end of the sixty (60) days period, then REGENTS may, at its
option, either terminate the Agreement or reduce LICENSEE's exclusive license
to a non-exclusive license by giving written notice to LICENSEE. These
notices shall be subject to Article 23 (Notices).

8.     PROGRESS AND ROYALTY REPORTS

       8.1    Prior to the Restatement Date, LICENSEE has submitted to REGENTS a
progress report covering LICENSEE's activities related to the development and
testing of all LICENSED PRODUCTS AND SERVICES and the obtaining of the
governmental approvals necessary, if any, for marketing in the United States.
These progress reports have been made for all LICENSED PRODUCTS AND SERVICES
prior to the first commercial sale of such LICENSED PRODUCTS AND SERVICES in the
United States.

       8.2    LICENSEE also agrees to report to REGENTS in its immediately
subsequent progress and royalty report, due on Jan. 1, 1999, the date of first
commercial distribution under license of LICENSED PRODUCTS AND SERVICES.

       8.3    After the first commercial distribution under license of LICENSED
PRODUCTS AND SERVICES by LICENSEE anywhere in the world, LICENSEE will make
quarterly royalty reports to REGENTS within sixty (60) days after the quarters
ending March 31, June 30, September 30, and December 31, of each year. Each such
royalty report shall include at least the following:

              (a)    The number of LICENSED PRODUCTS AND SERVICES manufactured
and the number of customers to whom LICENSED PRODUCTS AND SERVICES were provided
or licensed;

              (b)    Gross revenue for LICENSED PRODUCTS AND SERVICES licensed;

              (c)    NET LICENSEE REVENUES pursuant to Article 2.6;

              (d)    Total SUBLICENSING REVENUES;

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 9                       Confidential

<PAGE>

              (e)    Total royalties due REGENTS on such NET LICENSEE REVENUES
and SUBLICENSING REVENUES; and

              (f)    Names and addresses of any new sublicensees along with a
summary of the non-confidential material terms of each new sublicense agreement
entered into during the reporting quarter.

       8.4    If no distribution under license of LICENSED PRODUCTS AND SERVICES
has been made during the report period, a statement to this effect is required.

9.     BOOKS AND RECORDS

       9.1    LICENSEE shall keep full, true, and accurate books of accounts
containing all particulars that may be necessary for the purpose of showing
the amount of royalties payable to REGENTS. Said books of accounts shall be
kept at LICENSEE's principal place of business or the principal place of
business of the appropriate division of LICENSEE to which this Agreement
relates. Said books and the supporting data shall be open at all reasonable
times during normal business hours upon reasonable notice, for five (5) years
following the end of the calendar year to which they pertain, to the
inspection and audit by an independent certified public accountant retained
by REGENTS for the purpose of verifying LICENSEE's royalty statement or
compliance in other respects with this Agreement. Such independent certified
accountant shall be bound to hold all information in confidence except as
necessary to communicate LICENSEE's non-compliance with this AGREEMENT to
REGENTS.

       9.2    The fees and expenses of REGENTS' representatives performing
such an examination shall be borne by REGENTS. However, if an error in
underpaid royalties to REGENTS of more than [***] of the total royalties due
for any year is discovered, then the fees and expenses of these
representatives shall be borne by LICENSEE.

10.    LIFE OF THE AGREEMENT

       10.1   Unless otherwise terminated by the operation of law or by acts of
the parties in accordance with the terms of this Agreement, this Agreement shall
be in force from the effective date recited on page one and shall remain in
effect for the life of the last-to-expire patent licensed under this Agreement.

       Any termination of this Agreement shall not affect the rights and
obligations set forth in the following articles:

                     Article 4     Sublicenses

                     Article 9     Books and Records

                     Article 10    Life of the Agreement

                     Article 13    Disposition of PRODUCTS on Hand Upon
                                   Termination

                     Article 16    Use of Names and Trademarks

                     Article 19    Indemnification

                     Article 24    Late Payments

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 10                      Confidential

<PAGE>

                     Article 26    Confidentiality

       10.3   Any termination of this Agreement shall not relieve LICENSEE of
its obligation to pay any monies due or owing at the time of such termination
and shall not relieve any obligations, of either party to the other party,
established prior to termination.

11.    TERMINATION BY REGENTS

       If LICENSEE should violate or fail to perform any term or covenant of
this Agreement, then REGENTS may give written notice of such default ("Notice
of Default") to LICENSEE. If LICENSEE should fail to repair such default
within sixty (60) days of the effective date of such notice, REGENTS shall
have the right to terminate this Agreement and the licenses herein by a
second written notice ("Notice of Termination") to LICENSEE. If a Notice of
Termination is sent to LICENSEE, this Agreement shall automatically terminate
on the effective date of such notice, Such termination shall not relieve
LICENSEE of its obligation to pay any royalty or license fees owing at the
time of such termination and shall not impair any accrued rights of REGENTS.
These notices shall be subject to Article 23 (Notices).

12.    TERMINATION BY LICENSEE

       12.1   LICENSEE shall have the right at any time to terminate this
Agreement in whole or as to any portion of REGENTS' PATENT RIGHTS by giving
notice in writing to REGENTS. Such notice of termination shall be subject to
Article 23 (Notices) and termination of this Agreement shall be effective
ninety (90) days from the effective date of such notice.

       12.2   Any termination pursuant to the above paragraph shall not
relieve LICENSEE of any obligation or liability accrued hereunder prior to
such termination or rescind anything done by LICENSEE or any payments made to
REGENTS hereunder prior to the time such termination becomes effective, and
such termination shall not affect in any manner any rights of REGENTS arising
under this Agreement prior to such termination.

13.    DISPOSITION OF PRODUCTS ON HAND UPON TERMINATION

       Upon termination of this Agreement LICENSEE shall have the privilege of
disposing of all previously made or partially made LICENSED PRODUCTS, but no
more, within a period of one hundred and twenty (120) days following the
effective date of termination, provided, however, that the sale of such LICENSED
PRODUCTS shall be subject to the terms of this Agreement including, but not
limited to, the payment of royalties at the rate and at the time provided herein
and the rendering of reports thereon.

14.    PATENT PROSECUTION AND MAINTENANCE

       14.1   REGENTS shall diligently prosecute and maintain the United States
and foreign patent applications and patents under REGENTS' PATENT RIGHTS using
counsel of its choice, provided that the continued use of such counsel at any
point in the patent prosecution process subsequent to initial filing of a U.S.
patent application covering the INVENTION, including preparation and filing of
divisions, substitutions, extensions, continuation-in-part applications, and
corresponding foreign applications, shall be subject to the approval of
LICENSEE. REGENTS shall promptly provide

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 11                      Confidential

<PAGE>

LICENSEE with copies of all relevant documentation so that LICENSEE may be
currently informed and apprised of the continuing prosecution and LICENSEE
agrees to keep this documentation confidential in accordance with Article 26
herein. LICENSEE may comment upon such documentation, provided, however, that
if LICENSEE has not commented upon such documentation prior to the deadline
for filing a response with the relevant government patent office, REGENTS
shall be free to respond appropriately without consideration of LICENSEE's
comments. LICENSEE and LICENSEE's patent counsel shall have the right to
consult with patent counsel chosen by REGENTS.

       14.2   REGENTS shall use all reasonable efforts to prepare or amend any
patent application to include claims reasonably requested by LICENSEE to protect
the products contemplated to be sold, or methods or procedures to be practiced
under this Agreement.

       14.3   Subject to Articles 14.4 and 14.6, all past, present, and future
costs for preparing, filing, prosecuting, and maintaining all United States and
foreign patent applications, and patents issuing thereon and contemplated by the
executed Letter Agreement dated January 13, 1995, and this Agreement and not
paid for by a third party shall be borne by LICENSEE, so long as the licenses
granted to LICENSEE herein are exclusive. If, however, REGENTS reduces the
exclusive licenses granted herein to non-exclusive licenses pursuant to Articles
7.3, 7.4, or 7.5 and REGENTS grants additional license(s), the costs of
preparing, filing, prosecuting and maintaining such patent applications and
patents shall be divided equally among the licensed parties from the effective
date of each subsequently granted license agreement.

       14.4   REGENTS shall file, prosecute and maintain, at the request of
LICENSEE, patent applications and patents covered by REGENTS' PATENT RIGHTS in
foreign countries, if available, and if LICENSEE so desires. LICENSEE must
notify REGENTS within nine (9) months of the filing of the corresponding United
States application of its decision to obtain foreign patents. The notice
concerning foreign filing shall be in writing and must identify the countries
desired. The absence of such a notice from LICENSEE to REGENTS within such nine
(9) month period shall be considered an election not to secure foreign rights.
REGENTS shall have the right to file patent applications at its own expense in
any country which LICENSEE has not included in the list of desired countries and
such application and resultant patents shall not be subject to this Agreement.

       14.5   All patents and patent applications under this Agreement shall be
held in the name of REGENTS, and shall be subject to the terms and provisions
hereof. REGENTS shall take into consideration LICENSEE's reasonable suggestions
in the preparation and prosecution of REGENTS' PATENT RIGHTS covering the
INVENTION in order to obtain the broadest claims and protection.

       14.6   LICENSEE's obligation to underwrite and to pay all domestic and
foreign patent filing, prosecution, and maintenance costs shall continue for
so long as this Agreement remains in effect, provided, however, that LICENSEE
may terminate its obligations with respect to any given patent application or
patent in any or all designated countries upon three (3) months written
notice to REGENTS. REGENTS will use its best efforts to curtail patent costs
when such a notice is received from LICENSEE. REGENTS may continue
prosecution and/or maintenance of such application(s) or patent(s) at its
sole discretion and expense; provided, however, that LICENSEE shall have no
further right or licenses thereunder.

15.    MARKING

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 12                      Confidential

<PAGE>

       Prior to the issuance of patents under REGENTS' PATENT RIGHTS, LICENSEE
agrees to mark LICENSED PRODUCTS AND SERVICES (or their containers or labels)
made, sold, licensed or otherwise disposed of by it in the United States under
the license granted in this Agreement with the words "Patent Pending," and
following the issuance in the United States of one or more patents under
REGENTS' PATENT RIGHTS, with the numbers of the REGENTS' PATENT RIGHTS. All
LICENSED PRODUCTS OR SERVICES shipped to, manufactured, or sold in other
countries shall be marked in such manner as to conform with the patent laws and
practice of such countries.

16.    USE OF NAMES AND TRADEMARKS

       Nothing contained in this Agreement shall be construed as conferring
any right to use in advertising, publicity or other promotional activities
any name, trademark, trade name, or other designation of either party hereto
(including any contraction, abbreviation, or simulation of any of the
foregoing). Unless required by law or consented to in writing by REGENTS, the
use of the name "The Regents of the University of California" or the name of
any University of California campus is expressly prohibited.

17.    LIMITED WARRANTIES

       17.1   REGENTS warrants to LICENSEE that it has the lawful right to grant
this license.

       17.2   These licenses and the associated INVENTION are provided without
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
WARRANTY, EXPRESSED OR IMPLIED. REGENTS MAKES NO REPRESENTATIONS OR WARRANTIES
THAT THE LICENSED PRODUCTS AND SERVICES OR LICENSED METHOD WILL NOT INFRINGE ANY
PATENT OR OTHER PROPRIETARY RIGHTS.

       17.3   IN NO EVENT WILL REGENTS BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR
CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THE LICENSE GRANTED HEREUNDER
OR THE USE OF THE INVENTION OR LICENSED PRODUCTS.

       17.4   Nothing in this Agreement is or shall be construed as:

              (a)    A warranty or representation by REGENTS as to the validity
or scope of any REGENTS' PATENT RIGHTS; or

              (b)    A warranty or representation that anything made, used,
sold, or otherwise disposed of under any license granted in this Agreement is or
will be free from infringement of patents of third parties; or

              (c)    An obligation to bring or prosecute actions or suits
against third parties for patent infringement, except as provided in Article 18;
or

              (d)    Conferring by implication, estoppel, or otherwise any
license or rights under any patents of REGENTS other than REGENTS' PATENT RIGHTS
as defined herein; or

              (e)    An obligation to furnish any know how, not provided in
REGENTS' PATENT RIGHTS.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 13                      Confidential

<PAGE>

18.    PATENT INFRINGEMENT

       18.1   In the event that LICENSEE shall learn of the substantial
infringement of any REGENTS' PATENT RIGHTS under this Agreement, LICENSEE
shall promptly inform REGENTS with reasonable evidence of such infringement.
Both parties to this Agreement agree that during the period and in a
jurisdiction where LICENSEE has exclusive rights under this Agreement,
neither will notify a third party of the infringement without first obtaining
consent of the other party, which consent shall not be unreasonably denied.
Both parties shall use their best efforts, in cooperation with each other, to
terminate such infringement without litigation.

       18.2   LICENSEE may request that REGENTS take legal action against the
infringement. Such request shall be made in writing and shall include reasonable
evidence of such infringement and damages to LICENSEE. If the infringing
activity has not been abated within ninety (90) days following the effective
date of such request, REGENTS shall have the right to:

              (a)    Commence suit on its own account; or

              (b)    Refuse to participate in such suit.

REGENTS shall give notice of its election in writing to LICENSEE by the end of
the 100th day after receiving notice of such request from LICENSEE, and absent
refusal to participate in such suit, shall commence suit promptly thereafter.
LICENSEE shall have the right to join or intervene at its own expense in any
such suit commenced by REGENTS.

LICENSEE may bring suit for patent infringement if, and only if, REGENTS elects
not to commence suit and if the infringement occurred during the period and in a
jurisdiction where LICENSEE had exclusive rights under this Agreement. However,
in the event LICENSEE elects to bring suit in accordance with this paragraph,
REGENTS may thereafter join such suit at its own expense.

       18.3   Such legal action as is decided upon shall be at the expense of
the party on whose account suit is brought and all recoveries recovered thereby
shall belong to such party, provided that legal action brought jointly by
REGENTS and LICENSEE (or by one such party with later joinder or intervention by
the other) and fully participated in by both, shall be shared jointly by them in
proportion to the share of expense paid by each party.

       18.4   Each party agrees to cooperate with the other in legal proceedings
instituted hereunder but at the expense of the party on account of whom suit is
brought. Such legal proceedings shall be controlled by the party bringing the
action, except that REGENTS may be represented by counsel of its choice, at its
sole expense, in any action brought by LICENSEE and LICENSEE may be represented
by counsel of its choice, at its sole expense, in any action brought by REGENTS.

19.    INDEMNIFICATION

       LICENSEE agrees, and agrees to require its sublicensees, to indemnify,
hold harmless, and defend REGENTS and its officers, employees, and agents;
sponsor(s) of the research that led to the INVENTION; and the inventors of
the patents and patent applications in REGENTS' PATENT RIGHTS

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 14                      Confidential

<PAGE>

and their employees against any and all liability, claims, suits, losses,
damages, costs, fees, and expenses for death, illness, personal injury,
property damage, and improper business practices arising out of the
manufacture, use, sale, lease or other disposition of the INVENTION, REGENTS'
PATENT RIGHTS, or LICENSED PRODUCTS AND SERVICES by LICENSEE, by its
sublicensees, or each of their customers.

20.    EXPORT CONTROLS

       LICENSEE understands that REGENTS are subject to United States laws and
regulations (including the Arms Export Control Act, as amended, and the Export
Administration Act of 1979), controlling the export of technical data, computer
software, laboratory prototypes and other commodities, and REGENTS' obligations
under this Agreement are contingent on compliance with such laws and
regulations. The transfer of certain technical data and commodities may require
a license from the cognizant agency of the United States Government and/or
written assurances by LICENSEE that LICENSEE shall not export such technical
data and/or commodities to certain foreign countries without prior approval of
such agency. REGENTS neither represent that a license shall not be required nor
that, if required, it shall be issued.

21.    FOREIGN GOVERNMENTAL APPROVAL OR REGISTRATION

       If this Agreement or any associated transaction is required by the law of
any nation to be either approved or registered with any governmental agency,
LICENSEE shall assume all legal obligations to do so.

22.    ASSIGNMENT

       This Agreement is binding upon and shall inure to the benefit of REGENTS,
its successors and assigns, provided, however, this Agreement shall be personal
to LICENSEE and assignable by LICENSEE only with the written consent of REGENTS,
which consent shall not be unreasonably withheld, except that LICENSEE may
freely assign this Agreement to an acquirer of all or substantially all of
LICENSEE's stock, assets or business.

23.    NOTICES

       All notices under this Agreement shall be deemed to have been fully given
when done in writing and deposited in the United States mail, registered or
certified, and addressed as follows:

       To REGENTS:          Office of Technology Licensing
                            2150 Shattuck Avenue, Suite 510
                            Berkeley, CA 94720-1620
                            Attn: Director (UC Case No.: B95-034)

       To LICENSEE:         Acacia Biosciences, Inc. 4136 Lakeside Drive
                            Richmond, CA 94806
                            Attn.: President

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 15                      Confidential

<PAGE>

       Either party may change its address upon written notice to the other
       party.

24.    LATE PAYMENTS

       In the event royalty payments or fees are not received by REGENTS when
due, LICENSEE shall pay to REGENTS interest charges at a rate of [***]. Such
interest shall be calculated from the date payment was due until actually
received by REGENTS.

25.    WAIVER

       25.1   The failure of either party to assert a right hereunder or to
insist upon compliance with any term or condition of this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other party.

       25.2   None of the terms, covenants, and conditions of this Agreement can
be waived except by the written consent of the party waiving compliance.

26.    CONFIDENTIALITY

       26.1   LICENSEE and REGENTS respectively shall hold the other party's
proprietary business, terms of this Agreement, patent prosecution material, and
technical information and other proprietary information in confidence and
against disclosure to third parties with at least the same degree of care as it
exercises to protect its own data and license agreements of a similar nature.

       26.2   Nothing contained herein shall in any way restrict or impair the
right of LICENSEE or REGENTS to use, disclose, or otherwise deal with any
information or data which:

              (a)    at the time of disclosure to a receiving party is generally
available to the public or thereafter becomes generally available to the public
by publication or otherwise through no act of the receiving party;

              (b)    the receiving party can show by written record was in its
possession prior to the time of disclosure to it hereunder and was not acquired
directly or indirectly from the disclosing party;

              (c)    is independently made available to the receiving party
without restrictions as a matter of right by a third party;

              (d)    is subject to disclosure under the California Public
Records Act or other requirements of law.

       26.3   It is understood that REGENTS shall be free to release to the
inventors and senior administrators employed by REGENTS the terms and conditions
of this Agreement upon their request. If such release is made, REGENTS shall
inform such employees of the confidentiality obligations set forth above and
shall request and use its best efforts to ensure that they do not disclose such
terms and conditions to others. it is further understood that should a third
party inquire whether a license to REGENTS' PATENT RIGHTS is available, REGENTS
may disclose the existence of this Agreement and the extent of the grant in
Article 3 to such third party, but shall not disclose the name of LICENSEE,
except where REGENTS are required to release information under either the
California Public Records

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 16                      Confidential

<PAGE>

Act or other applicable law, provided REGENTS shall give prior written notice
to LICENSEE of such disclosure.

       26.4   LICENSEE and REGENTS agree to destroy or return to the disclosing
party proprietary information received from the other in its possession within
fifteen (15) days following the effective date of termination of this Agreement.
However, each party may retain one copy of proprietary information of the other
solely for archival purposes in non-working files for the sole purpose of
verifying the ownership of the proprietary information, provided such
proprietary information shall be subject to the confidentiality provisions set
forth in Article 26.1. LICENSEE and REGENTS agree to provide each other, within
thirty (30) days following termination of this Agreement, with a written notice
that proprietary information has been returned or destroyed.

       26.5   The terms of this Article 26 (Confidentiality) shall expire in
five (5) years from the official date of termination of this Agreement.

27.    FORCE MAJEURE

       The parties to this Agreement shall be excused from any performance
required hereunder if such performance is rendered impossible or unfeasible due
to any catastrophes or other major events beyond their reasonable control,
including, without limitation, war, riot, and insurrection; laws, proclamations,
edicts, ordinances, or regulations; strikes, lockouts, or other serious labor
disputes; and floods, fires, explosions, or other natural disasters. When such
events have abated, the parties' respective obligations hereunder shall resume.

28.    SEVERABILITY

       The provisions of this Agreement are severable, and in the event that
any provision of this Agreement shall be determined to be invalid or
unenforceable under any controlling body of law, such invalidity or
enforceability shall not in any way affect the validity or enforceability of
the remaining provisions hereof.

29.    APPLICABLE LAW

       THIS AGREEMENT SHALL BE CONSTRUED, INTERPRETED, AND APPLIED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF CALIFORNIA. QUESTIONS CONCERNING THE LAW AND
EFFECT OF THE REGENTS' PATENT RIGHTS SHALL BE DETERMINED BY THE LAW OF THE
COUNTRY IN WHICH THE PATENT WAS GRANTED.

30.    SCOPE OF AGREEMENT

       This Agreement (except for the Letter Agreement dated January 13, 1995
and extension thereof, which shall continue to the extent it is not inconsistent
with this Agreement) incorporates the entire agreement between the parties with
respect to the subject matter hereof, and this Agreement may be altered. or
modified only by written amendment duly executed by the parties hereto.

       IN WITNESS WHEREOF, the parties hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 17                      Confidential

<PAGE>

THE REGENTS OF THE                        ACACIA BIOSCIENCES, INC.
UNIVERSITY OF CALIFORNIA

By: /s/: William A. Hoskins               By: /s/: Bruce Cohen
    ---------------------------------        ----------------------------------
         William A. Hoskins                        Bruce Cohen
         Director                                  President and Chief Executive
         Office of Technology Licensing            Officer

Date: January 4, 1999                     Date: December 23, 1998
     --------------------------------          --------------------------------

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                    Page 18                      Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]